Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T40909
(Former ID: TTDI01645)
|
|||||
| Target Name |
Rhinovirus Protease 3C (HRV P3C)
|
|||||
| Synonyms |
Rhinovirus P3C
Click to Show/Hide
|
|||||
| Gene Name |
HRV P3C
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Virus infection [ICD-11: 1A24-1D9Z] | |||||
| Function |
Capsid protein VP1: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome. Capsid protein VP1 mainly forms the vertices of the capsid. Capsid protein VP1 interacts with host VLDLR to provide virion attachment to target host cells. This attachment induces virion internalization. Tyrosine kinases are probably involved in the entry process. After binding to its receptor, the capsid undergoes conformational changes. Capsid protein VP1 N-terminus (that contains an amphipathic alpha-helix) and capsid protein VP4 are externalized. Together, they shape a pore in the host membrane through which viral genome is translocated to host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).
Click to Show/Hide
|
|||||
| UniProt ID | ||||||
| EC Number |
EC 3.4.22.28
|
|||||
| Sequence |
MSLIKHNSCVITTENGKFTGLGVYDRFVVVPTHADPGKEIQVDGITTKVIDSYDLYNKNG
IKLEITVLKLDRNEKFRDIRRYIPNNEDDYPNCNLALLANQPEPTIINVGDVVSYGNILL SGNQTARMLKYSYPTKSGYCGGVLYKIGQVLGIHVGGNGRDGFSAMLLRSYFTDVQGQIT LS Click to Show/Hide
|
|||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
| 1 | Rupintrivir | Drug Info | Phase 2 | Virus infection | [2] | |
| Mode of Action | [+] 1 Modes of Action | + | ||||
| Modulator | [+] 1 Modulator drugs | + | ||||
| 1 | Rupintrivir | Drug Info | [1] | |||
| Drug Binding Sites of Target | Top | |||||
|---|---|---|---|---|---|---|
| Ligand Name: Lauric acid | Ligand Info | |||||
| Structure Description | HUMAN RHINOVIRUS SEROTYPE 2 (HRV2) | PDB:1FPN | ||||
| Method | X-ray diffraction | Resolution | 2.60 Å | Mutation | No | [3] |
| PDB Sequence |
LVVPNINSSN
24 PTTSNSAPAL34 DAAETGHTSS44 VQPEDVIETR54 YVQTSQTRDE64 MSLESFLGRS 74 GCIHESKLEV84 TLANYNKENF94 TVWAINLQEM104 AQIRRKFELF114 TYTRFDSEIT 124 LVPCISALSQ134 DIGHITMQYM144 YVPPGAPVPN154 SRDDYAWQSG164 TNASVFWQHG 174 QAYPRFSLPF184 LSVASAYYMF194 YDGYDEQDQN204 YGTANTNNMG214 SLCSRIVTEK 224 HIHKVHIMTR234 IYHKAKHVKA244 WCPRPPRALE254 YTRAHRTNFK264 IEDRSIQTAI 274 VTRPIITTA
|
|||||
|
|
ILE77
4.640
TRP97
4.783
ILE99
3.349
ASN100
3.561
LEU101
3.184
GLN102
3.032
PHE119
4.772
SER121
3.804
ILE123
3.686
TYR145
4.104
PHE180
4.648
|
|||||
| Click to View More Binding Site Information of This Target and Ligand Pair | ||||||
| Ligand Name: Vapendavir | Ligand Info | |||||
| Structure Description | Structure of HRV2 capsid complexed with antiviral compound BTA798 | PDB:3VDD | ||||
| Method | X-ray diffraction | Resolution | 3.20 Å | Mutation | No | [4] |
| PDB Sequence |
ENYIDEVLNE
13 VLVVPNINSS23 NPTTSNSAPA33 LDAAETGHTS43 SVQPEDVIET53 RYVQTSQTRD 63 EMSLESFLGR73 SGCIHESKLE83 VTLANYNKEN93 FTVWAINLQE103 MAQIRRKFEL 113 FTYTRFDSEI123 TLVPCISALS133 QDIGHITMQY143 MYVPPGAPVP153 NSRDDYAWQS 163 GTNASVFWQH173 GQAYPRFSLP183 FLSVASAYYM193 FYDGYDEQDQ203 NYGTANTNNM 213 GSLCSRIVTE223 KHIHKVHIMT233 RIYHKAKHVK243 AWCPRPPRAL253 EYTRAHRTNF 263 KIEDRSIQTA273 IVTRPIITTA283
|
|||||
|
|
ILE99
3.585
ASN100
4.163
LEU101
3.157
GLN102
4.721
PHE119
4.190
SER121
3.520
ILE123
3.598
TYR143
3.356
MET144
3.746
TYR145
3.207
ALA167
3.152
SER168
4.129
VAL169
4.296
PHE180
3.210
|
|||||
| Click to View More Binding Site Information of This Target with Different Ligands | ||||||
| Different Human System Profiles of Target | Top |
|---|---|
|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Similarity Proteins
|
|
|
There is no similarity protein (E value < 0.005) for this target
|
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J Virol. 2011 Oct;85(19):10319-31. | |||||
| REF 2 | In Vitro Resistance Study of Rupintrivir, a Novel Inhibitor of Human Rhinovirus 3C Protease . Antimicrob Agents Chemother. 2007 December; 51(12): 4366-4373. | |||||
| REF 3 | Structure of human rhinovirus serotype 2 (HRV2). J Mol Biol. 2000 Jul 28;300(5):1179-94. | |||||
| REF 4 | An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus. ACS Med Chem Lett. 2012 Feb 13;3(4):303-7. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.